Balaxi Pharmaceuticals (BALAXI) investor relations material

Business overview and strategy

• Focuses on branded, IPR-driven pharmaceuticals in frontier markets, especially Latin America and Africa, with a strong presence in OTC and branded generics segments.

• Operates an asset-light model, now transitioning to asset-right with its first manufacturing facility in Hyderabad for backward integration and global expansion.

• Deep distribution network with 38 warehouses and on-ground fleet, supported by digital procurement and regulatory management tools.

• Targets top-2 market positions in each geography, leveraging local regulatory compliance and a motivated expatriate leadership team.

• Expansion underway in new Latin American markets, with 980 product registrations and over 200 more in the pipeline.

Financial performance

• Q1 FY27 revenue grew 14% YoY to ₹80.68 crore, with gross profit margin up 241 bps to 46.5%.

• Profit after tax for Q1 FY27 rose to ₹1.29 crore from ₹0.29 crore YoY, with EPS up 380%.

• FY26 revenue declined 7.7% YoY to ₹270.17 crore, with EBITDA margin dropping to 4.2% and PAT margin to 0.5%.

• Management expects further improvement as operating leverage strengthens and strategic initiatives mature.

Operations and product portfolio

• Commercial production commenced at the Hyderabad facility, focusing on general oral solid dosage for Latin America and Africa.

• Product mix includes branded and generic medicines, with a broad therapeutic portfolio: antibiotics, analgesics, anti-malaria, vitamins, and more.

• Q1 FY27 product sales split: 54% branded, 46% generics; 60% tablets, 40% injectables/liquids.

• 16 new product registrations in Q1 FY27, total portfolio now at 980 registered products.